This online CME activity addresses interdisciplinary strategies for improving outcomes in patients with tenosynovial giant cell tumor (TGCT). Faculty review the disease spectrum, including diffuse and localized subtypes, and highlight clinical features that warrant early referral to specialists. The program examines evidence from clinical trials of CSF1R inhibitors, with a focus on functional endpoints and patient-reported outcomes that capture the real-world impact of therapy on mobility, pain, and quality of life. Participants will learn how to apply trial findings to select appropriate treatment approaches tailored to disease burden and functional impairment. The session also emphasizes proactive management of adverse events associated with systemic therapy, including monitoring, early intervention, and supportive care strategies to maintain safety and adherence.